Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.…
Phathom Pharmaceuticals Marks GERD Awareness Week 2026 by Urging Americans to Take Frequent Heartburn Seriously
Phathom Pharmaceuticals (NASDAQ: PHAT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 371 employees.
The shares were at 4.660 USD on 20 November 2026, down 64.3% over 52 weeks. Its 52-week range is 4.615 USD to 18.31 USD, and it trades at the bottom of that range.
Its market capitalisation is 378.82M USD.
Phathom Pharmaceuticals reports return on equity of 50.5%, an operating margin of -9.3% and revenue up 71.1% year over year.
Its debt exceeds its cash by 370.89M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 25 February 2027.